EUVIMEDEUVIMED entdecken
Crossref

Deconvoluting Biophysical Factors that Influence Long-Term Aggregation Rates of High-Concentration Monoclonal Antibody Formulations

James K Forder iD, Erinc Sahin, Christopher J Roberts iD

Molecular Pharmaceutics · 05.01.2026 · 23 (1) · 502-516

DOI: 10.1021/acs.molpharmaceut.5c01398 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 11.12.2025. Verfasst von James K Forder und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical and Biomolecular Engineering, University of Delaware, Newark, Delaware 19713, United States. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Protein Aggregates. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 114 Literaturangaben. Gefördert von: Bristol Myers Squibb Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Efficient determination of developable protein drug candidates and stable solution conditions is a key challenge in industrial drug development. Protein aggregation is difficult to predict and can lead to challenges in manufacturing, storage, and patient safety. In this work, stability of four monoclonal antibodies (MAbs) were studied at a wide range of solution conditions and incubation temperatures intended to systematically evaluate attributes that can influence aggregation rates. The studies were conducted as a function of pH, ionic strength, MAb concentrations, and incubation temperatures that were representative of industrial stability studies. Results were analyzed in the contexts of conformational stability and net self-interactions. Interpretable machine learning models were applied to parse and quantify the phenomena relevant to high-concentration aggregation rates, with emphasis on refrigerated conditions representative of common storage conditions for MAb products. The results indicated that the aggregation rates were non-Arrhenius, and stability studies at 30 to 50 °C were broadly misleading with respect to the stability rankings of the different formulations and MAbs in comparison to the stability rankings at refrigerated storage conditions. For this set of MAbs and formulation conditions, the net valence was the most significant predictor of aggregation rates at refrigerated storage conditions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalProtein AggregatesHydrogen-Ion ConcentrationTemperatureDrug CompoundingProtein StabilityOsmolar ConcentrationDrug StabilityHumansDrug StorageChemistry, PharmaceuticalMachine Learning

Stichwörter der Autor:innen

biopharmaceutical characterizationbiophysical modelsbiotechnologydevelopabilitymachine learningmonoclonal antibodiesprotein aggregationprotein formulation

Substanzen

Antibodies, MonoclonalProtein Aggregates

Autor:innen und Institutionen

  • Department of Chemical and Biomolecular Engineering, University of Delaware, Newark, Delaware 19713, United States.
  • Drug Product Development, Bristol Myers Squibb, New Brunswick, New Jersey 08901, United States.

ORCID-Profile: James K Forder, Christopher J Roberts

Förderung

  • Bristol Myers Squibb Foundation

Zitieren

APA

Forder, J. K., Sahin, E., & Roberts, C. J. (2026). Deconvoluting Biophysical Factors that Influence Long-Term Aggregation Rates of High-Concentration Monoclonal Antibody Formulations. Molecular Pharmaceutics, 23(1), 502-516. https://doi.org/10.1021/acs.molpharmaceut.5c01398

Vancouver

Forder JK, Sahin E, Roberts CJ. Deconvoluting Biophysical Factors that Influence Long-Term Aggregation Rates of High-Concentration Monoclonal Antibody Formulations. Molecular Pharmaceutics. 2026;23(1):502-516. doi:10.1021/acs.molpharmaceut.5c01398

BibTeX
@article{Forder2026,
  author = {Forder, James K and Sahin, Erinc and Roberts, Christopher J},
  title = {Deconvoluting Biophysical Factors that Influence Long-Term Aggregation Rates of High-Concentration Monoclonal Antibody Formulations},
  journal = {Molecular Pharmaceutics},
  year = {2026},
  volume = {23},
  number = {1},
  pages = {502--516},
  doi = {10.1021/acs.molpharmaceut.5c01398}
}
Kostenlos starten →